Table 3. Patient clinical and immunophenotypical characteristics of patients with DLBCL, NOS in relation to DHS and THS.

		MYC/BCL2				MYC/BCL6				BCL2/BCL6				MYC/BCL2/BCL6
Characteristic	All patients(n = 336)	DHS 0(n = 90)	DHS 1(n = 151)	DHS 2(n = 95)	P	DHS 0(n = 57)	DHS 1(n = 173)	DHS 2(n = 106)	P	DHS 0(n = 65)	DHS 1(n = 156)	DHS 2(n = 115)	P	THS 0(n = 27)	THS 1(n = 131)	THS 2(n = 109)	THS 3(n = 69)	P
	N (%)	N (%)	N (%)	N (%)		N (%)	N (%)	N (%)		N (%)	N (%)	N (%)		N (%)	N (%)	N (%)	N (%)
LDH>ULN	129 (38)	28 (31)	52 (34)	49 (52)	0.007	17 (30)	61 (35)	51 (48)	0.035	23 (35)	57 (37)	49 (43)	0.512	7 (26)	47 (36)	38 (35)	37 (54)	0.024
ECOG PS ≥2	51 (15)	8 (9)	20 (13)	23 (24)	0.010	6 (11)	24 (14)	21 (20)	0.228	4 (6)	26 (17)	21 (18)	0.073	2 (7)	12 (9)	23 (21)	14 (20)	0.025
Stage III/IV	156 (46)	36 (40)	73 (48)	47 (49)	0.355	19 (33)	80 (46)	57 (54)	0.044	28 (43)	67 (43)	61 (53)	0.215	12 (44)	47 (36)	63 (58)	34 (49)	0.008
Extranodal sites ≥2	57(17)	13 (14)	30 (20)	14 (15)	0.440	8 (14)	31 (18)	18 (17)	0.795	11 (17)	23 (15)	23 (20)	0.522	4 (15)	20 (15)	22 (20)	11 (16)	0.751
IPI score of 3–5	83 (25)	14 (16)	39 (26)	30 (32)	0.038	7 (12)	43 (25)	33 (31)	0.029	11 (17)	36 (23)	36 (31)	0.081	3 (11)	23 (18)	36 (33)	21 (30)	0.009
Immunohistochemical subgroups
CD5-positive	15 (4)	2 (2)	7 (5)	6 (6)	NS*	3 (5)	3 (2)	9 (8)	NS*	0 (0)	8 (5)	7 (6)	NS*	0 (0)	5 (4)	4 (4)	6 (9)	NS*
GCB	90 (27)	29 (32)	48 (32)	13 (14)	0.004 #	21 (37)	50 (29)	19 (18)	0.034 #	33 (51)	38 (24)	19 (17)	<0.001 #	12 (44)	47 (36)	21 (19)	10 (14)	0.001 #
non-GCB	231 (69)	59 (66)	96 (63)	76 (80)		33 (58)	120 (69)	78 (74)		32 (49)	110 (71)	89 (77)		15 (56)	79 (60)	84 (77)	53 (77)

P values were derived using Pearson’s Chi-Square test. Bold font indicates significance.

*NS, not suitable for chi-square test among CD5+ vs. GCB vs. non-GCB, because more than 1/5 of the expected values were less than five.

^# P value GCB vs. non-GCB.